12 April 2024
12 April 2024
Alpine’s lead asset, povetacicept, is slated to enter Phase III trials in the second half of this year.
The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.
The Fujifilm site expansion is set to add 680 jobs to the site and expand Fujifilm’s contract research business and production capacity across North America.
The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.
The collaboration pact will see Rallybio gaining a $6.6m equity investment from J&J to further a natural history study of FNAIT.
Moderna has not secured vaccine orders from any African nation since 2022.
Novartis will make $1.01bn in milestone payments for ARV-766 to Arvinas.
The acquisition is aimed at enhancing Eliem’s portfolio with a clinical-stage programme targeting unmet needs in autoimmune diseases.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
